Filing Flows › Comparisons › IONS vs SUPN
Ionis Pharmaceuticals vs Supernus Pharmaceuticals: IONS and SUPN compared
Ionis Pharmaceuticals is the larger company: $243M of revenue in its latest quarter (Q3 2026) against $227M for Supernus Pharmaceuticals (Q3 2026). Ionis Pharmaceuticals is growing faster (+55% against +18% a year earlier). Supernus Pharmaceuticals is more profitable, with an operating margin of 9.3% against -53.8%.
Where the money goes: IONS and SUPN
Ionis Pharmaceuticals (IONS) · Q3 2026
Ionis Pharmaceuticals, Q3 2026: revenue $243M (+55% year over year), operating margin -53.8%, net loss $110M, operating cash flow −$179M. The chart follows the revenue to costs, profit and cash.
Supernus Pharmaceuticals (SUPN) · Q3 2026
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
| Ionis Pharmaceuticals (IONS) | Supernus Pharmaceuticals (SUPN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $243M | $227M |
| Revenue growth, Y/Y | +55% | +18% |
| Operating margin | -53.8% | 9.3% |
| Net earnings | −$110M | $20.9M |
| Net margin | -45.3% | 9.2% |
| Operating cash flow | −$179M | $6.6M |
| Free cash flow | — | $6.4M |
| Market value | $7.1B | — |
| Analysts’ mean target | $84.13 | — |
Where the revenue comes from
Ionis Pharmaceuticals
- Commercial Revenue: $136M (56%)
- Research and Development Revenue: $107M (44%)
Supernus Pharmaceuticals
- Net product sales: $179M (79%)
- ONAPGO: $17.1M (8%)
- Trokendi XR: $10.2M (5%)
- Oxtellar XR: $8.0M (4%)
Questions
Which is bigger, Ionis Pharmaceuticals or Supernus Pharmaceuticals?
Ionis Pharmaceuticals is the larger company: $243M of revenue in its latest quarter (Q3 2026) against $227M for Supernus Pharmaceuticals (Q3 2026).
Is Ionis Pharmaceuticals or Supernus Pharmaceuticals growing faster?
Ionis Pharmaceuticals is growing faster (+55% against +18% a year earlier).
Which is more profitable, Ionis Pharmaceuticals or Supernus Pharmaceuticals?
Supernus Pharmaceuticals is more profitable, with an operating margin of 9.3% against -53.8%.
More: Ionis Pharmaceuticals earnings · how Ionis Pharmaceuticals makes money · Supernus Pharmaceuticals earnings · how Supernus Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.